These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15107257)

  • 41. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
    Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
    [No Abstract]   [Full Text] [Related]  

  • 42. Online tool to guide decisions for BRCA1/2 mutation carriers.
    Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
    J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations.
    Metcalfe KA
    Womens Health (Lond); 2009 Jan; 5(1):63-8. PubMed ID: 19102642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
    Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
    Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preventive oophorectomy in women exhibiting BRCA mutations].
    Roseau E
    Presse Med; 2003 Feb; 32(4):149-50. PubMed ID: 12613483
    [No Abstract]   [Full Text] [Related]  

  • 47. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations.Gynécol Obstét Fertil 2003;31:370-377].
    Stoppa-Lyonnet D
    Gynecol Obstet Fertil; 2003 Oct; 31(10):888-9; author reply 889. PubMed ID: 14642951
    [No Abstract]   [Full Text] [Related]  

  • 50. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
    van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
    J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Preventive Intervention of Hereditary Breast Cancer.
    Cao A; Huang L; Shao Z
    Adv Exp Med Biol; 2017; 1026():41-57. PubMed ID: 29282679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study.
    Brandberg Y; Arver B; Johansson H; Wickman M; Sandelin K; Liljegren A
    Eur J Surg Oncol; 2012 Jan; 38(1):38-43. PubMed ID: 22032910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene.
    Taucher S; Gnant M; Jakesz R
    Langenbecks Arch Surg; 2003 Mar; 388(1):3-8. PubMed ID: 12690474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of hereditary breast and ovarian cancer.
    Yamauchi H; Takei J
    Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
    S Chapman J; Roddy E; Panighetti A; Hwang S; Crawford B; Powell B; Chen LM
    Clin Breast Cancer; 2016 Dec; 16(6):494-499. PubMed ID: 27495996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer.
    Eisen A; Rebbeck TR; Wood WC; Weber BL
    J Clin Oncol; 2000 May; 18(9):1980-95. PubMed ID: 10784640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.